Skip to content

Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia

Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03870243
Enrollment
1240
Registered
2019-03-12
Start date
2019-09-02
Completion date
2022-07-27
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Pneumonia

Keywords

Bubble CPAP, Young Children, Severe Pneumonia, Hypoxemia, Treatment failure, Mortality

Brief summary

Principal Investigator: Mohammod Jobayer Chisti Research Protocol Title: Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial Proposed start date: 1st July 2018, Estimated end date: 31st December 2022 Background: Feasibility and acceptability followed by effectiveness of bubble continuous positive airway pressure (CPAP) were not evaluated in childhood severe pneumonia in developing countries at a larger scale. Objectives: Stages I and II * To assess the feasibility and acceptability (not only by patients' care-givers but also by physicians and nurses) of bubble CPAP in treating childhood severe pneumonia in two tertiary hospitals in Stage I and in two district hospitals in Stage II * To record adverse events following use of bubble CPAP in these settings * To understand how much resource and time are needed to institutionalize and maintain bubble CPAP as a routine practice in the health system Stage III: * To determine therapeutic efficacy/effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure in children admitted to hospitals with severe pneumonia and hypoxemia * To determine therapeutic effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure & mortality in children aged 1-12 months admitted to hospitals with severe pneumonia and hypoxemia * To record adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia) encountered.

Detailed description

Methodology: Cluster randomized controlled clinical trial Methodology: 1. Stages I and II: Feasibility/demonstration stage will be done as an internal pilot in 3 hospitals a. Current treatment practice, facilities, and operational challenges will be evaluated for the introduction, clinical use and maintenance of bubble CPAP 2. Stage III: Implementation of bubble CPAP will be done in 12 hospitals a. It will be done following a cluster randomized design Data collection-socio-demographic and clinical data will be collected using structured questionnaire by trained nurses and physicians. Research Site: St. Paulos Millennium Medical College, Yekatit 12 and Tikur Anbessa Specialized hospitals, 14 district hospitals Number of Participants/Patients: Stage I-30 children in each tertiary hospital (this stage has completed and we enrolled 49 children from two tertiary hospitals; these 49 enrolled children took double of our anticipated time {4 months}) Stage II- 20 children in each general hospital (2 general/district hospitals, we have enrolled total 40 children from this two hospitals from January 2020 to July 2020, which included COVID-19 period) Stage III-1240 children in 12 general/district hospitals (620 in bubble CPAP arm and 620 in WHO standard low flow arm; each hospital will be the cluster and 6 will be randomized to each arm) Main Inclusion Criteria: * Age between 1 month and 59 months * Meet WHO clinical criteria for severe pneumonia with hypoxemia * Hypoxemia (Oxygen saturation \<90% in room air) * Parent/guardian gives informed consent to participate in the study Statistical Analysis: * STATA -14: for initial two phases descriptive analysis of level of feasibility and acceptability will be performed * For the phase III: We shall follow the principle of intention to treat. --Treatment failure and/or death will be analyzed using χ² or Fisher's exact tests as appropriate. * Primary and secondary outcomes will be compared by calculating relative risks (RRs) and their 95% confidence intervals. * Log-linear binomial regression will be applied to adjust for covariates to evaluate the true impact of bubble CPAP in evaluating primary and secondary outcomes and to adjust for baseline differences. * Continuous variables will be analyzed using the Student t-test or the Mann-Whitney test as appropriate. Study Duration: 48 months.

Interventions

To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia

To see the effectiveness of low flow oxygen in children with severe pneumonia

Sponsors

Armauer Hansen Research Institute (AHRI), Ethiopia
CollaboratorUNKNOWN
International Centre for Diarrhoeal Disease Research, Bangladesh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

As it was an open-labeled randomized controlled clinical trial, there was no masking in any intervention.

Intervention model description

Children aged 1-59 months with Severe Pneumonia in Ethiopia, divided in two arms; one arm will get bCPAP other arm will get WHO recommended low flow oxygen.

Eligibility

Sex/Gender
ALL
Age
1 Months to 59 Months
Healthy volunteers
No

Inclusion criteria

* Age between 1 month and 59 months, * Meet WHO clinical criteria for severe pneumonia with hypoxemia. * Oxygen saturation \<90% despite standard flow oxygen therapy * Parent/guardian gives informed consent to participate in the study

Exclusion criteria

* Known congenital heart disease, asthma, or upper -airway obstruction * Tracheostomy * Pneumothorax * Needs mechanical ventilation for any specific reason as decided by the clinician

Design outcomes

Primary

MeasureTime frameDescription
For stage I and II feasibility and acceptability of bubble CPAP in two tertiary and two district hospitals will be measured in number and reported in percentage7 monthsPatient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure
For stage III: Primary outcome: Treatment failure12-18 months (Mid April 2021 to Mid October 2022)According to this protocol treatment failure will be declared if the following criteria are met: A. Presence of severe hypoxemia (SpO2\<85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization All will be measured in number and reported in percentage.

Secondary

MeasureTime frameDescription
Secondary outcomes: • Death • Adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia ) encountered12-18 months (Mid April 2021 to Mid October 2022)All will be measured in number and reported in percentage.

Other

MeasureTime frameDescription
Length of hospital stay in days12-18 months (Mid April 2021 to Mid October 2022)Length of hospital stay will be measured and reported in days.
Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage12-18 months (Mid April 2021 to Mid October 2022)Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage.
Incidence of nasal trauma, gastric distention, shock and air leaks in number12-18 months (Mid April 2021 to Mid October 2022)Incidence of nasal trauma, gastric distention, shock and air leaks will be measured in number and reported in percentage.
Duration of bCPAP in hour12-18 months (Mid April 2021 to Mid October 2022)Duration of bCPAP will be measured and reported in hour/hours.

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026